Shenzhen Oculgen Biomedical Technology Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Shenzhen Oculgen Biomedical Technology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. (NCT07520318) | Shenzhen Oculgen Biomedical Technology Co., Ltd. | 2026-04-17 |
Track Shenzhen Oculgen Biomedical Technology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.